Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...
EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback